Skip to content
DataLookout
Menu

NCT07914166

Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Incidence of dose limiting toxicity (DLT)
Timeframe: Up to 2 cycles (Cycle length = 28 days)
Maximum tolerated dose/recommended phase 2 dose
Timeframe: Up to the 18.6 months

Secondary (8)

Incidence of adverse events (AEs)
Complete molecular response
Complete response (CR)/CR with incomplete hematologic recovery
Minimal residual disease negativity
Rate of allogeneic hematopoietic cell transplantation
Show 3 moreShow less
Overall survival (OS)
Progression-free survival (PFS)
Concentration of asciminib (Pharmacokinetics)

Arms and interventions

Treatment (asciminib-based induction therapy)Experimental

Patients receive asciminib PO QD or BID on days 1-28 of cycles 1 and 2 and days 1-42 of cycle 3, triple IT chemotherapy on days 1 and 14 of cycles 1 and 2 and days 1, 14, 28, and 42 of cycle 3, dexamethasone PO on days 1-4 and 11-14 of cycle 1, vincristine IV on days 1 and 14 of cycle 1, and blinatumomab IV on days 1-28 of cycle 2 and days 15-42 of cycle 3. Cycles repeat every 28 days (cycles 1 and 2) or 42 days (cycle 3) for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO during screening, blood and CSF sample collection on study, and bone marrow aspiration throughout the study.

Drugs: Asciminib, Corticosteroid, Cytarabine, Dexamethasone, Methotrexate, Vincristine

Procedures: Biospecimen Collection, Bone Marrow Aspiration, Echocardiography Test

Biologicals: Blinatumomab

Sites

1 site in 1 country

  • City of Hope Medical CenterDuarte, California, United States